Kjelsåsveien 168 B
319 articles with Nordic Nanovector
Nordic Nanovector ASA announces that it will report its results for the first quarter 2020 on Tuesday, 26 May 2020.
Nordic Nanovector Announces US Patent Granted Covering the use of Betalutin® to Sensitise B-Cell Cancer Cells to CD20 Immunotherapy
Nordic Nanovector ASA is pleased to announce the grant of a US patent covering the use of Betalutin® for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy.
Nordic Nanovector ASA (OSE: NANO) today announces changes to its Executive Management Team.
Nordic Nanovector ASA announces a new date for its Annual General Meeting as a result of the impact of the ongoing COVID-19 pandemic.
Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021
Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial with Betalutin® in advanced follicular lymphoma (FL) as well as to extend its cash runway into 2021. A webcast will take place on Thursday 2 April at 10:00 am CET . Details below. At the time
On 26 March 2020, the Board of Directors of Nordic Nanovector ASA approved the company's financial statements for 2019.
The Board of Directors of Nordic Nanovector ASA has on 24 March 2020 decided to grant 561,500 Performance Share Units to employees in accordance with the authorisation granted at the Annual General Meeting held on 25 April 2019.
Financial calendar for Nordic Nanovector ASA
Nordic Nanovector ASA announces its results for the fourth quarter and full year 2019.
Nordic Nanovector ASA (OSE: NANO) announces that Dr Lars Nieba has been appointed interim Chief Executive Officer with immediate effect.
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2019 Results Presentation and Webcast
OSLO, Norway , Feb. 21, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the fourth quarter and full year 2019 on Thursday, 27 February 2020. A presentation by Nordic Nanovector's senior management team will take place at 8:30am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: VIPPETANGEN
Nordic Nanovector Awarded NOK 12 Million in Funding From the Norwegian Research Council to Advance Alpha37, a Targeted Alpha Therapy for B-cell Cancers
Nordic Nanovector ASA announces that its research and development project Nanoyield has received a non-dilutive funding of NOK 12 million from the Norwegian Research Council.
Nordic Nanovector ASA reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation.
The Board of Directors of Nordic Nanovector ASA has on 10th December 2019 resolved to grant Dr Lars Nieba, Chief Technology Officer, 50,000 Performance Share Units in connection with his appointment and under the Company's equity incentive plan that was approved at the Company's annual general meeting held on 25 April 2019.
Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin®-Based Therapies in NHL
Nordic Nanovector ASA announces that new data from preclinical studies investigating the effect of Betalutin® on non-Hodgkin's lymphoma cell lines will be presented in a poster at the 61st American Society of Hematology Annual Meeting & Exposition.
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
The Board of Directors of Nordic Nanovector ASA has on 19th November 2019 resolved to grant Dr Gabriele Elbl, Vice President Global Regulatory Affairs, 30,000 Performance Share Units in connection with her appointment and under the Company's equity incentive plan that was approved at the Company's annual general meeting held on 25 April 2019
Nordic Nanovector ASA announces its results for the third quarter 2019.
Nordic Nanovector ASA announces that it will report its results for the third quarter 2019 on Tuesday, 19 November 2019.
Tone Kvåle, CFO, has purchased 5,000 shares in Nordic Nanovector ASA at an average share price of NOK 19.96 per share.